Pulmonary Pharmacology and Therapeutics

Aims & Scope

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects.

The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery.

Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection.

In addition to original research papers the journal will include review articles and book reviews.

Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.8

SJR (SCImago Journal Rank)

Year	Value
2024	0.790

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	84

Journal Rank

Year	Value
2024	6899

Journal Citation Indicator

Year	Value
2024	471

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway

  Citation: 267

  Authors: Sophie, Bruce A., George A.

• The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

  Citation: 262

  Authors: Armin, Esteban J., Giuseppe, Serge, Shahin, Rolf, Christian, Hermann

• Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review

  Citation: 256

  Authors: A.M., B., W.A.

• Reactive Oxygen Species as Mediators in Asthma

  Citation: 230

  Authors: Paul A.J., Frans P.

• The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD

  Citation: 196

  Authors: Mario, Mathieu

• Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.

  Citation: 195

  Authors: S., F., F., P., A., N., P.A., L., A.

• cAMP regulation of airway smooth muscle function

  Citation: 188

  Authors: Charlotte K., Oluwaseun O., Raymond B., Satoru

• Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes

  Citation: 184

  Authors: Uwe R., Tanja, Kurt, Meinolf, Adrian, Hans

• Resolvin D1 protects mice from LPS-induced acute lung injury

  Citation: 155

  Authors: Bin, Xia, Jing-yuan, Li, Zhuo, Hong-zhong, Su

• Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2–Keap1 signaling

  Citation: 151

  Authors: Narayanan, Srinivasan, Ganapasam

---